BOISE, Idaho, Aug. 27, 2018 /PRNewswire/ -- Burst Biologics is pleased to announce an exciting new milestone: its research
This new research study from Burst Biologics demonstrates the clinical utility of dehydrated amniotic membrane, a placental tissue known for its regenerative properties. It's a significant achievement for Burst's research to be published in Regenerative Medicine, one of the most impactful journals in the "Biomedical Engineering" category.
The Regenerative Medicine publication is edited under Dr. Chris Mason, Professor of Regenerative Medicine in the Advanced Centre for Biochemical Engineering at University College London. Inclusion in the journal requires peer review by two or more members of the International Editorial Board to ensure that the article is scientifically accurate and clinically relevant, and all identities are kept confidential to ensure lack of bias.
"We're pleased that our latest scientific study has been validated by scientists of such stature," said Christopher D. Jones, founder and CEO of Burst Biologics. "Our company will continue advancing the field of regenerative medicine by letting the data guide us toward tomorrow's medical breakthroughs."
About Burst BiologicsBurst Biologics is a rapidly-growing medical research and biotechnology company providing hospitals and clinicians with a range of powerful regenerative therapies derived from cord blood, placental tissue, and bone. With a commitment to harnessing the power of biology, the research team at Burst Biologics is conducting industry-leading research in areas like musculoskeletal, immuno-oncology, and CNS diseases. Visit the Burst Biologics research page to learn more.
View original content:http://www.prnewswire.com/news-releases/new-study-from-burst-biologics-featured-in-regenerative-medicine-journal-300702191.html
SOURCE Burst Biologics
Subscribe to our Free Newsletters!